Paloma Partners’s Rein Therapeutics RNTX Stock Holding History

Paloma Partners’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,295	Closed	-$140K	–	2007
2018 Q2	$140K	Buy	+1,295	New	+$147K	﹤0.01%	1512

Other funds holding RNTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLF

Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Paloma Partners's RNTX Position: Q3 2018 in Review

Paloma Partners sold out of Rein Therapeutics (RNTX) in Q3 2018, closing a stake of 1,295 shares — an estimated $140K sold.

Paloma Partners first reported a position in RNTX in Q2 2018 and held it in 1 quarter. The position peaked at $140K in Q2 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q3 2018.

Paloma Partners reported no remaining Rein Therapeutics position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 1,295 Rein Therapeutics shares in Q3 2018, an estimated $140K.
Paloma Partners first reported a position in Rein Therapeutics in Q2 2018 and held it in 1 quarter.
Paloma Partners's Rein Therapeutics position peaked at $140K in Q2 2018.
23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.